Extracellular matrix secretion

Extracellular matrix (ECM) secretion is a complex biological process involving the synthesis, post-translational modification, and exocytosis of structural proteins, glycosaminoglycans, and proteoglycans into the extracellular space [1]. This process is primarily mediated by fibroblasts and is essential for maintaining tissue integrity, providing mechanical support, and facilitating intercellular communication [2]. In healthy tissues, ECM secretion is tightly regulated to balance synthesis and degradation; however, dysregulation leads to pathological conditions such as fibrosis, where excessive deposition of collagen impairs organ function [3]. In the context of oncology, aberrant ECM secretion contributes to the formation of a dense stroma that promotes tumor progression and limits drug delivery [4]. While 'extracellular matrix secretion' is a physiological process rather than a single molecular target, therapeutic strategies often focus on inhibiting the signaling pathways (e.g., TGF-beta, PDGF) or enzymes (e.g., LOXL2) that drive this secretion to treat fibrotic diseases and certain cancers [5]. Drugs such as pirfenidone and nintedanib are currently used to slow the progression of fibrosis by modulating these underlying secretory and activation pathways [6].

Other names

ECM secretionMatrix depositionExtracellular matrix productionFibrogenesisMatrix protein exocytosis

Modulation of profibrotic signaling pathways (e.g., TGF-beta inhibition), inhibition of tyrosine kinases involved in fibroblast activation, and direct inhibition of matrix-crosslinking enzymes to reduce the deposition of structural proteins.